Clinical Trial

QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

Name: QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma — clinical trial record (NCT07049185)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: QICE-ESCC

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single-arm, Simon's two-stage phase II clinical trial to evaluate the efficacy and safety of QL1706 (a dual PD-1 and CTLA-4 antibody) combined with celecoxib in patients with advanced esophageal squamous cell carcinoma (ESCC) who progressed after prior immune checkpoint inhibitor therapy.

Trial Details

NCT Number	NCT07049185
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	Esophageal Squamous Cell Carcinoma
Enrollment	35 participants
Start Date	2025-07-15
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-03